Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12304MR)

This product GTTS-WQ12304MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12304MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ16009MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ15083MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ8956MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ11714MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ10272MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ8532MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ4138MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ2824MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW